Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicentre, single-arm, open-label efficacy, pharmacokinetics, and safety study to demonstrate non-inferiority of prolgolimab 250 mg every 3 weeks versus historical data for prolgolimab 1 mg/kg every 2 weeks in patients with unresectable or metastatic melanoma, as well as collecting pharmacokinetics and safety data.

The study is conducted under the same conditions as the previously conducted study BCD-100-2/MIRACULUM. This means that this Study No. BCD-100-8/FLAT has identical parameters such as:

* selection criteria for subjects in the study, defining the population,
* research centers,
* procedures for evaluating effectiveness and safety,
* permitted prior and concomitant therapy of the underlying disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

NCT05732805

Melanoma Melanoma (Skin) Melanoma Stage III +4 more

ACTIVE_NOT_RECRUITING PHASE3

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

NCT02306850

Unresectable Malignant Neoplasm Melanoma Metastatic Melanoma +2 more

COMPLETED PHASE2

Expanded Access Program With Nivolumab to Treat Melanoma

NCT02142218

Stage III (Unresectable) or Stage IV Advanced Melanoma

NO_LONGER_AVAILABLE

A Study of RO5185426 in Patients With Metastatic Melanoma

NCT01248936

Malignant Melanoma

COMPLETED PHASE2

Biomarkers in Immunotherapy of Melanoma

NCT05878977

Metastatic Melanoma Immune Checkpoints Inhibitors Gastrointestinal Microbiome (Bacterial and Viral) +1 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unresectable or Metastatic Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Group Type EXPERIMENTAL

Prolgolimab

Intervention Type DRUG

250 mg Q3W

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prolgolimab

250 mg Q3W

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent and the subject's ability to comply with the protocol requirements.
* Age ≥18 years at the time of informed consent.
* Histologically confirmed unresectable or metastatic melanoma (with available documented evidence of relevant examinations).
* Primarily detected advanced or metastatic melanoma, or the disease progression on or after previous systemic therapy.
* Measurable target tumor lesions (at least 1 lesion) according to RECIST 1.1 criteria, confirmed by an independent reviewer.
* ECOG score 0-1.
* Absence of severe organ and system disorders.
* Life expectancy of at least 12 weeks at screening.
* For patients of childbearing potential: willingness to use reliable methods of contraception throughout the study, from the time of informed consent and for up to 6 weeks after the last dose of the study drug.
* Available blocks for a histological examination and/or the patient's consent for collection of biopsy43 samples to obtain histological material to assess the PD-L1 status.

Exclusion Criteria

* Patients with severe concomitant disorders, life-threatening acute complications of the primary disease (including massive pleural, pericardial, or peritoneal effusions requiring intervention, pulmonary lymphangitis) at the time of informed consent.
* CNS metastases that are progressing or associated with clinical symptoms (e.g., cerebral edema, spinal compression) or requiring the use of glucocorticosteroids and/or anticonvulsants;
* Ongoing concomitant diseases at the time of screening increasing the risk of severe adverse events during the study treatment.
* The need for glucocorticoids or any other drugs with immunosuppressive effects.
* Hematologic abnormalities.
* Renal impairment.
* Hepatic impairment.
* Increased LDH \>2 ULN.
* Prior treatment with anti-CTLA4 and/or anti-PD-1/PD-L1/PDL-2 drugs.
* Prior targeted therapy.
* A history of malignancies, except for radically treated diseases in remission for over 5 years prior to starting the study.
* Conditions limiting the patient's ability to comply with the protocol requirements (dementia, neurologic or mental disorders, drug or alcohol addiction, etc).
* Simultaneous participation in other clinical studies55 or participation in other clinical studies within 30 days prior to starting the study treatmen.
* Acute infections or activation of chronic infectious diseases within 28 days prior to the beginning of the study treatment.
* Active hepatitis B, active hepatitis C, HIV-infection, syphilis.
* Impossibility to administer the study drug intravenously.
* Impossibility to perform imaging examinations requiring administration of intravenous contrast media.
* Hypersensitivity to any of the components of BCD-100.
* A history of hypersensitivity to monoclonal antibody products.
* Pregnancy or breastfeeding.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No